DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception. 20 Jun 2018
DolPHIN 2 Trial Manager and Trial Monitor to visit Cape Town site The DolPHIN 2 trial opened for recruitment in our South African site last month. 05 Feb 2018
The first participant has been recruited to the DolPHIN 2 trial! On 22nd January 2018, our South African site opened to recruitment with the very first participant recruited into the DolPHIN-2 clinical trial the very next day. 25 Jan 2018
The Liverpool team sets off for Uganda: IDI Site Initiation Visit Today marks an important step in the set-up of the DolPHIN 2 trial, as key members of the Liverpool team make their way to Uganda for a Site Initiation Visit (SIV). 09 Oct 2017
11th March 2024 British Science Week Parliamentary Reception We showcased the DolPHIN-2 work at a parliamentary reception for British Science Week at the Houses of Parliament. London, UK
2nd - 7th Dec 2019 ICASA Conference 2019 The DolPHIN 2 team will have a stand in the community village at the ICASA conference. Come along, say hello and learn more about the programme! Kigali, Rwanda
7th- 8th May 2019 3rd Annual Consortium Meeting Project teams from UCT, IDI, Radboudumc, LSTM and University of Liverpool converged in Cape Town for our third annual consortium meeting. Under discussion was the progress of the main DolPHIN2 trial so far as well as other potential sub-studies arising from our initial data. Cape Town, South Africa
27th -29th March 2017 DolPHIN-2 Consortium meeting After months of teleconferences, the DolPHIN-2 project team finally came face to face at our first consortium meeting Cape Town, South Africa